Arcutis Biotherapeutics Stock EBITDA

ARQT Stock

USD 10.77 0.63 6.21%

Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.

		Last Reported	Projected for Next Year
	EBITDA	-227.4 M	-216.1 M

EBITDA is likely to gain to about (216.1 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arcutis Biotherapeutics Company EBITDA Analysis

Arcutis Biotherapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Arcutis Biotherapeutics EBITDA

(227.43 M)

Most of Arcutis Biotherapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcutis Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arcutis EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Arcutis Biotherapeutics is extremely important. It helps to project a fair market value of Arcutis Stock properly, considering its historical fundamentals such as EBITDA. Since Arcutis Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcutis Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcutis Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Net Receivables	Short Term Debt	Common Stock	Property Plant Equipment	Intangible Assets
Total Assets		0.87	0.92	0.53	-0.82	0.94	0.86	0.82	0.93	0.78	0.97	1.0	1.0	0.53	0.93	0.96	0.82	-0.34
Total Stockholder Equity	0.87		0.95	0.28	-0.57	0.77	0.54	0.59	0.8	0.38	0.93	0.88	0.88	0.26	0.76	0.9	0.6	-0.18
Net Tangible Assets	0.92	0.95		0.4	-0.71	0.9	0.67	0.65	0.88	0.52	0.96	0.92	0.91	0.44	0.87	0.95	0.72	-0.27
Net Debt	0.53	0.28	0.4		-0.84	0.61	0.71	0.33	0.69	0.64	0.57	0.52	0.51	0.81	0.73	0.57	0.85	-0.63
Retained Earnings	-0.82	-0.57	-0.71	-0.84		-0.89	-0.9	-0.74	-0.94	-0.83	-0.79	-0.82	-0.8	-0.92	-0.94	-0.86	-0.99	0.75
Accounts Payable	0.94	0.77	0.9	0.61	-0.89		0.91	0.8	0.94	0.8	0.92	0.94	0.93	0.69	0.98	0.94	0.89	-0.44
Long Term Debt	0.86	0.54	0.67	0.71	-0.9	0.91		0.86	0.85	0.95	0.78	0.86	0.85	0.75	0.92	0.81	0.9	-0.5
Long Term Debt Total	0.82	0.59	0.65	0.33	-0.74	0.8	0.86		0.78	0.81	0.67	0.82	0.82	0.58	0.75	0.78	0.72	-0.48
Capital Surpluse	0.93	0.8	0.88	0.69	-0.94	0.94	0.85	0.78		0.74	0.92	0.93	0.92	0.77	0.97	0.98	0.95	-0.63
Total Liab	0.78	0.38	0.52	0.64	-0.83	0.8	0.95	0.81	0.74		0.65	0.78	0.77	0.68	0.8	0.67	0.79	-0.42
Net Invested Capital	0.97	0.93	0.96	0.57	-0.79	0.92	0.78	0.67	0.92	0.65		0.97	0.96	0.5	0.93	0.96	0.8	-0.3
Total Current Assets	1.0	0.88	0.92	0.52	-0.82	0.94	0.86	0.82	0.93	0.78	0.97		1.0	0.53	0.93	0.96	0.82	-0.34
Net Working Capital	1.0	0.88	0.91	0.51	-0.8	0.93	0.85	0.82	0.92	0.77	0.96	1.0		0.51	0.92	0.95	0.81	-0.33
Net Receivables	0.53	0.26	0.44	0.81	-0.92	0.69	0.75	0.58	0.77	0.68	0.5	0.53	0.51		0.76	0.65	0.9	-0.91
Short Term Debt	0.93	0.76	0.87	0.73	-0.94	0.98	0.92	0.75	0.97	0.8	0.93	0.93	0.92	0.76		0.95	0.95	-0.54
Common Stock	0.96	0.9	0.95	0.57	-0.86	0.94	0.81	0.78	0.98	0.67	0.96	0.96	0.95	0.65	0.95		0.88	-0.51
Property Plant Equipment	0.82	0.6	0.72	0.85	-0.99	0.89	0.9	0.72	0.95	0.79	0.8	0.82	0.81	0.9	0.95	0.88		-0.75
Intangible Assets	-0.34	-0.18	-0.27	-0.63	0.75	-0.44	-0.5	-0.48	-0.63	-0.42	-0.3	-0.34	-0.33	-0.91	-0.54	-0.51	-0.75

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Arcutis Biotherapeutics

Ebitda Over Time

Arcutis Ebitda

Ebitda

(216.06 Million)

At this time, Arcutis Biotherapeutics' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Arcutis Biotherapeutics reported earnings before interest,tax, depreciation and amortization of (227.43 Million). This is 125.92% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 105.83% higher than that of the company.

Arcutis EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcutis Biotherapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics of similar companies.

Arcutis Biotherapeutics is currently under evaluation in ebitda category among its peers.

Arcutis Biotherapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	830.3M	1.0B	1.0B	223.9M	257.4M	244.6M
Enterprise Value	767.3M	943.2M	1.0B	341.4M	392.6M	373.0M

Arcutis Biotherapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Arcutis Biotherapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Arcutis Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcutis Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcutis Biotherapeutics' value.

		Shares
Geode Capital Management, Llc	2024-09-30	2.5 M
Ensign Peak Advisors Inc	2024-09-30	2.4 M
Cormorant Asset Management, Llc	2024-09-30	2.3 M
Pivotal Bioventure Partners Investment Advisor Llc	2024-06-30	2 M
Deutsche Bank Ag	2024-06-30	1.9 M
Stempoint Capital Lp	2024-09-30	1.8 M
D. E. Shaw & Co Lp	2024-09-30	1.7 M
Gw&k Investment Management, Llc	2024-09-30	1.6 M
J. Goldman & Co Lp	3124-09-30	1.5 M
Jennison Associates Llc	2024-09-30	11.7 M
Suvretta Capital Management, Llc	2024-06-30	10 M

Arcutis Fundamentals

	Return On Equity	-1.92
	Return On Asset	-0.31
	Profit Margin	(1.41) %
	Operating Margin	(0.87) %
	Current Valuation	1.06 B
	Shares Outstanding	117.05 M
	Shares Owned By Insiders	2.10 %
	Shares Owned By Institutions	97.90 %
	Number Of Shares Shorted	27.76 M
	Price To Book	7.58 X
	Price To Sales	9.09 X
	Revenue	59.61 M
	Gross Profit	2.93 M
	EBITDA	(227.43 M)
	Net Income	(262.14 M)
	Cash And Equivalents	282.17 M
	Cash Per Share	5.47 X
	Total Debt	205.92 M
	Debt To Equity	0.40 %
	Current Ratio	10.75 X
	Book Value Per Share	1.34 X
	Cash Flow From Operations	(247.06 M)
	Short Ratio	16.78 X
	Earnings Per Share	(1.77) X
	Price To Earnings To Growth	(0.31) X
	Target Price	19.0
	Number Of Employees	296
	Beta	1.19
	Market Capitalization	1.26 B
	Total Asset	341.37 M
	Retained Earnings	(981.9 M)
	Working Capital	283.76 M
	Current Asset	87.18 M
	Current Liabilities	4.42 M
	Net Asset	341.37 M

About Arcutis Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC